Accentia Files Reorganization Plan

Kellerhals, Richard
June 2010
High Yield Report;6/7/2010, Vol. 21 Issue 23, p18
The article reports on the reorganization plan field by Accentia Biopharmaceuticals with U.S. Bankruptcy Court for the Middle District of Florida in Tampa, Florida on June 1, 2010.


Related Articles

  • Financings Roundup.  // BioWorld Today;6/16/2011, Vol. 22 Issue 116, p2 

    This section offers news briefs concerning finance in the biotechnology sector, including the 4 million dollars worth of convertible notes that will be received by Accentia Biopharmaceuticals Inc., the 10 million dollar loan received by NuPathe Inc. and PharmAthene Inc.'s 5.8 million dollars in...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;6/8/2009, Vol. 17 Issue 21, p4 

    The article reports that an experimental treatment from Accentia Biopharmaceuticals Inc. have shown to delay the return of lymphoma, a cancer of immune cells, by more than a year among patients who achieved remission after chemotherapy. The findings have boosted prospects for weapons against the...

  • ACCENTIA REPORTS FISCAL YEAR-END NET LOSS OF $76.0 MIL.  // Biotech Financial Reports;Feb2008, Vol. 15 Issue 2, p1 

    The article reports on the financial performance of Accentia Biopharmaceuticals Inc. in 2007 in Tampa, Florida. The company has recorded a decline in net sales from $25.1 millions to $18.3 million compared to 2006. It states that the company's consolidated research and development costs...

  • Panel's Nod on Lymphoma Trial Ramps Up Success Speculation. Hollingsworth, Catherine // BioWorld Today;4/18/2008, Vol. 19 Issue 76, p1 

    The article reports on an announcement by Tampa, Florida-based Biovest International Inc. that an independent committee reviewing its BiovaxID cancer vaccine trial has called for the unblinding of study data for conducting a final analysis. The shares of Accentia Biopharmaceuticals, parent...

  • CLINIC ROUNDUP.  // BioWorld Today;8/1/2007, Vol. 18 Issue 148, p6 

    This section offers news briefs on clinical trials. Accentia Biopharmaceuticals Inc. filed a preliminary new drug application with the U.S. Food and Drug Administration (FDA) for Revimmune, which is indicated for multiple sclerosis. Javelin Pharmaceuticals Inc. will commence a Phase III trial of...

  • BioWorld Stock Report For Public Biotechnology Companies.  // BioWorld Insight;2/ 4/2013, Vol. 21 Issue 6, p17 

    A table is presented which provide data on stock report from "BioWorld" for public biotechnology companies as of February 2013 including Accentia Biopharmaceuticals, Cell Therapeutics, and Ventrus Biosciences.

  • Accentia Tumbles on Negative SinuNase Data.  // Bioworld Week;3/31/2008, Vol. 16 Issue 13, p3 

    The article reports that Accentia Biopharmaceuticals Inc. Phase III clinical trial for SinuNase (amphotericin B) failed to meet its main objective of completing resolution of two key symptoms: congestion and sinusitis. However, the firm noted that the full data may support superior efficacy of...

  • New Analysis Shows Benefit for Accentia's SinuNase. Hollingsworth, Catherine // BioWorld Today;5/1/2008, Vol. 19 Issue 85, p1 

    The article reports on the plan of Accentia Biopharmaceuticals Inc. to continue development of its nasal syringe SinuNase for chronic sinusitis. The plan came after an analysis of CT scans and endoscopy data showed that it helped patients with severe inflammation. The company believes that...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/5/2008, Vol. 19 Issue 216, p2 

    This section offers news briefs related to biotechnology. Accentia Biopharmaceuticals Inc. has decided not to appeal a Nasdaq decision to delist Accentia's shares of common stock from the Nasdaq Capital Market. A research was published by Alnylam Pharmaceuticals Inc. with collaborators in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics